Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Once a broad tumor class is established, more specific differentiation markers can be pursued (e.g., lineage-restricted transcription factors for adenocarcinoma; p40 for squamous cell carcinoma; chromogranin A and synaptophysin or INSM1 for neuroendocrine neoplasms).
|
31786484 |
2020 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The SSP was developed in 68 NSCLC tumors of adenocarcinoma (AC), squamous cell carcinoma (SqCC) and large-cell neuroendocrine carcinoma (LCNEC) histology, based on NanoString expression of 11 (CHGA, SYP, CD56, SFTPG, NAPSA, TTF-1, TP73L, KRT6A, KRT5, KRT40, KRT16) relevant genes for IHC-based NSCLC histology classification.
|
30914778 |
2019 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In order to check the assumption that p63 is a useful marker for squamous cellular differentiation, we used two antibodies: anti-p63 and anti-thyroid transcription factor-1 (TTF-1), based on their immunoexpression to differentiate small cell lung carcinoma (SCLC) from poorly differentiated nonkeratinizing squamous cell carcinoma (SCC).
|
31263838 |
2019 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although P40 staining for the sarcomatous component was positive along with squamous carcinoma, E-cadherin expression disappeared while vimentin was expressed.
|
31366562 |
2019 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
As there are few data from South Africa, we aimed to determine utility of TTF-1, napsin A, p63 and CK5 immunostaining on fine needle aspiration (FNA) cell block and formalin-fixed paraffin-embedded tissue biopsy specimens in subtyping NSCLC as adenocarcinoma and squamous cell carcinomas.
|
31206846 |
2019 |
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this study we demonstrate that TP63 directly regulates NRG1 expression in human SCC cell lines and that NRG1 is a critical component of the TP63 transcriptional program.
|
31144617 |
2019 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Proteins associated with regulation of the sonic hedgehog pathway, and the Nfe2l2 response, Tp63, and Keap1 and p62/SQSTM1 proteins, showed differential expression in larynx, oral and lung high TrkB1-T1 expresser SCCs.
|
31221127 |
2019 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
ZNF185 is a p63 target gene critical for epidermal differentiation and squamous cell carcinoma development.
|
30337687 |
2019 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Sensitivity of CK5/6, p40, and p63 for SqCC was 93%, 94%, and 94% and specificity was 98%, 97%, and 84%, respectively.
|
30798982 |
2019 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Both lesions were squamous cell carcinoma and positive for p40.
|
31845086 |
2019 |
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
D2-40 and P63 expression highlighted both PAC and SCC and seems to be useful in excluding metastatic BrCa with a sensitivity and specificity of 58% and 100%, and 98% and 100%, respectively.
|
29781860 |
2018 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cytokeratin 5/6 (CK5/6), p63, and p40 are commonly used as immunohistochemical markers for squamous cell carcinoma (SqCC) of the lung.
|
30546464 |
2018 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
ROCK-dependent phosphorylation of NUP62 regulates p63 nuclear transport and squamous cell carcinoma proliferation.
|
29217659 |
2018 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Super-Enhancer-Driven Long Non-Coding RNA LINC01503, Regulated by TP63, Is Over-Expressed and Oncogenic in Squamous Cell Carcinoma.
|
29454790 |
2018 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, epigenomic profilings of different types of SCCs reveal that TP63 and SOX2 cooperatively and lineage-specifically regulate long non-coding RNA (lncRNA) CCAT1 expression, through activation of its super-enhancers and promoter.
|
30190462 |
2018 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
As tumor cells showed positive immunostaining for p40 and CK5/6, the immunophenotype of the tumor was consistent with squamous cell carcinoma (SCC).
|
30216599 |
2018 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We further define the interactions of keratinocyte PKK with TP63 and NF-κB signaling, highlighting the importance of this protein as a tumor suppressor in SCC development.
|
29186361 |
2018 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
For differential diagnosis, immunostaining markers such as CK5/6 and p63 can be used to distinguish SCC and CK7 for adenocarcinoma.
|
27889037 |
2017 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Immunohistochemistry assay confirmed the positive expression of CK5/6 and p63 in pancreatic SCC.
|
28099906 |
2017 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Ber EP4 and MOC 31 immunostains were positive in most cases when performed, and the most specific immunostains for SCC were p63 and p40.Negative mucin stains were helpful.
|
29024544 |
2017 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The sensitivities of p40, p63 and cytokeratin 5/6 were 100% with specificities of 88%, 46% and 81%, respectively, for SCC.
|
29187465 |
2017 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
CD44 and p63 are identified as candidate stem cell markers in normal squamous epithelium and SCC.
|
28645102 |
2017 |
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The higher protein level of p63 in SCC was attenuated by the transfection of PKC-δ.
|
28756980 |
2017 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We characterized captured cells using TTF1 and p40 as immunostaining biomarkers of adenocarcinoma and squamous cell carcinoma, respectively.
|
28298147 |
2017 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
ACTL6A Is Co-Amplified with p63 in Squamous Cell Carcinoma to Drive YAP Activation, Regenerative Proliferation, and Poor Prognosis.
|
28041841 |
2017 |